Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis

DSpace/Manakin Repository

Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis
 
Khan, Faizan; Tritschler, Tobias; Kimpton, Miriam; Wells, Philip S; Kearon, Clive; Weitz, Jeffrey I; Büller, Harry R; Raskob, Gary E; Ageno, Walter; Couturaud, Francis; Prandoni, Paolo; Palareti, Gualtiero; Legnani, Cristina; Kyrle, Paul A; Eichinger, Sabine; Eischer, Lisbeth; Becattini, Cecilia; Agnelli, Giancarlo; Vedovati, Maria Cristina; Geersing, Geert-Jan; Takada, Toshihiko; Cosmi, Benilde; Aujesky, Drahomir; Marconi, Letizia; Palla, Antonio; Siragusa, Sergio; Bradbury, Charlotte A; Parpia, Sameer; Mallick, Ranjeeta; Lensing, Anthonie W A; Gebel, Martin; Grosso, Michael A; Shi, Minggao; Thavorn, Kednapa; Hutton, Brian; Le Gal, Gregoire; Rodger, Marc; Fergusson, Dean
(2021) Journal of thrombosis and haemostasis : JTH, volume 19, issue 11, pp. 2801 - 2813
(Article)
Abstract
BACKGROUND: The long-term risk for recurrent venous thromboembolism (VTE) during extended anticoagulation for a first unprovoked VTE is uncertain. OBJECTIVES: To determine the incidence of recurrent VTE during extended anticoagulation of up to 5 years in patients with a first unprovoked VTE. METHODS: MEDLINE, EMBASE, and the Cochrane CENTRAL were ... read more
Download/Full Text
The full text of this publication is not available.
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: anticoagulant therapy, prognosis, pulmonary embolism, systematic review, venous thromboembolism, Hematology
DOI: https://doi.org/10.1111/jth.15491
ISSN: 1538-7933
Publisher: Wiley-Blackwell
Note: Funding Information: FK, T Tritschler, MK, PW, CK, JW, SP, KT, GLG, MR, and DF are members of the CanVECTOR Network; the Network receives grant funding from the Canadian Institutes of Health Research (Funding Reference: CDT‐142654). FK holds the Frederick Banting and Charles Best doctoral research scholarship from the Canadian Institutes of Health Research. JW holds the Canada Research Chair (Tier I) in Thrombosis and the Heart and Stroke Foundation of Canada J. F. Mustard Chair in Cardiovascular Research. T Tritschler holds an Early Postdoc. Mobility Award from the Swiss National Science Foundation (SNSF P2ZHP3_177999) and a Fellowship Award from the CanVECTOR Network. GLG holds the Chair on Diagnosis of Venous Thromboembolism at the Department of Medicine, University of Ottawa, and a Clinician‐Scientist Award from the Heart and Stroke Foundation of Canada. MR is the McGill University Harry Webster Thorp Professor of Medicine. Funding Information: FK, T Tritschler, MK, PW, CK, JW, SP, KT, GLG, MR, and DF are members of the CanVECTOR Network; the Network receives grant funding from the Canadian Institutes of Health Research (Funding Reference: CDT-142654). FK holds the Frederick Banting and Charles Best doctoral research scholarship from the Canadian Institutes of Health Research. JW holds the Canada Research Chair (Tier I) in Thrombosis and the Heart and Stroke Foundation of Canada J. F. Mustard Chair in Cardiovascular Research. T Tritschler holds an Early Postdoc. Mobility Award from the Swiss National Science Foundation (SNSF P2ZHP3_177999) and a Fellowship Award from the CanVECTOR Network. GLG holds the Chair on Diagnosis of Venous Thromboembolism at the Department of Medicine, University of Ottawa, and a Clinician-Scientist Award from the Heart and Stroke Foundation of Canada. MR is the McGill University Harry Webster Thorp Professor of Medicine. Funding Information: PW reports receiving honoraria for advisory board meetings from Bayer Healthcare, Sanofi, and Daiichi Sankyo, and Research Funding from BMS/Pfizer. JW reports serving as a consultant for which he has received honoraria from Bayer, Boehringer Ingelheim, Bristol‐Myers Squibb, Daiichi Sankyo, Ionis, Janssen, Merck, Novartis, Pfizer, Anthos, PhaseBio, Itreas, and Servier, outside the submitted work. GR reports receiving consultancy fees or honoraria from Anthos, Bristol‐Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Janssen, Novartis, Pfizer, Portola, and Tetherex; and personal fees from Bayer Healthcare, Bristol‐Myers Squibb, Boehringer Ingelheim, Eli Lilly, Daiichi Sankyo, Janssen, Pfizer, Portola, Itreas, Tetherex, Anthos, and Novartis, outside the submitted work. WA reports grants from Bayer, and personal fees from Bayer, Daiichi Sankyo, Boehringer Ingelheim, BMS Pfizer, Aspen, Sanofi, Portola, and Janssen, outside the submitted work. FC reports receiving research grant support from Pfizer, fees for board memberships or symposia from Bayer, Bristol‐Myers Squibb/Pfizer and Astra Zeneca, and travel support from Bayer, Bristol‐Myers Squibb/Pfizer, Daiichi Sankyo, Boehringer Ingelheim, Leo Pharma, Intermune and Actelion, outside the submitted work. GP reports serving on advisory boards for Alfasigma, Pfizer, BMS and Roche, outside the submitted work. CB reports receiving personal fees from Bayer HealthCare, Bristol Myers Squibb, and Daiichi Sankyo, outside the submitted work. GA reports receiving personal fees from Bristol Myers Squibb, Bayer HealthCare, and Daiichi Sankyo, outside the submitted work. BC reports receiving personal fees from Daiichi Sankyo, Werfen, and Sanofi, outside the submitted work. SS reports grants from Bayer, SOBI, NOVARTIS, and personal fees from Bayer, Sobi, Novartis, Amgen, and Janssen, outside the submitted work. TL and MG report being an employee of Bayer. M. Grosso and MS report being employees of Daiichi Sankyo. BH reports receiving honoraria from Cornerstone Research Group for provision of methodologic advice related to systematic reviews and meta‐analysis. GLG reports other support from Portola Pharmaceuticals, Boehringer Ingelheim, Pfizer, BristolMyers Squibb, LEO Pharma, Daiichi Sankyo, Bayer, Sanofi, and bioMerieux, outside the submitted work. The remaining authors declare no competing financial interests. Publisher Copyright: © 2021 International Society on Thrombosis and Haemostasis.
(Peer reviewed)